EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer

Jong Chul Park iD, Donghoon Shin iD

JCO Precision Oncology · 2024-08 · (8)

DOI: 10.1200/po.24.00179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2024-08. Verfasst von Jong Chul Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Immunoconjugates, Head and Neck Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 129 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are fusions of therapeutic drugs and antibodies conjugated by a linker, designed to deliver a therapeutic payload to cells expressing the target antigen. By delivering the highly cytotoxic agent directly to cancer cells, ADCs are designed to enhance safety and broaden the therapeutic window. Recently, ADCs have demonstrated promising efficacy in various solid tumors and are rapidly expanding their indications. The prognosis of patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor, with no new therapeutics since the advent of anti–PD-1 antibodies in 2016, highlighting a critical need for innovative therapies. Recent preliminary results suggest that ADCs could be promising treatment options for HNSCC as they explore a variety of target antigens, payloads, and linkers. However, for successful adaptation of ADCs in the treatment of HNSCC, addressing key challenges such as payload toxicities, antigen heterogeneity, and adaptive resistance will be essential. Current research focused on new ADC structures, including multispecific antibodies and noncytotoxic payloads, and diverse combination approaches, show promise for future advancements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesHead and Neck NeoplasmsHumansSquamous Cell Carcinoma of Head and NeckDrug Development

Substanzen

Immunoconjugates

Autor:innen und Institutionen

  • Massachusetts General Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA.

ORCID-Profile: Jong Chul Park, Donghoon Shin

Zitieren

APA

Park, J. C., & Shin, D. (2024). Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.24.00179

Vancouver

Park JC, Shin D. Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.24.00179

BibTeX
@article{Park2024,
  author = {Park, Jong Chul and Shin, Donghoon},
  title = {Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.24.00179}
}
Kostenlos starten →